🇺🇸 Glycopyrronium/Formoterol Fumarate in United States
88 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 88
Most-reported reactions
- Death — 28 reports (31.82%)
- Chronic Obstructive Pulmonary Disease — 12 reports (13.64%)
- Pneumonia — 9 reports (10.23%)
- Dyspnoea — 6 reports (6.82%)
- Influenza — 6 reports (6.82%)
- Nasopharyngitis — 6 reports (6.82%)
- Wheezing — 6 reports (6.82%)
- Asthma — 5 reports (5.68%)
- Full Blood Count Abnormal — 5 reports (5.68%)
- Obstructive Airways Disorder — 5 reports (5.68%)
Other Respiratory / Pulmonology approved in United States
Frequently asked questions
Is Glycopyrronium/Formoterol Fumarate approved in United States?
Glycopyrronium/Formoterol Fumarate does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Glycopyrronium/Formoterol Fumarate in United States?
AstraZeneca is the originator. The local marketing authorisation holder may differ — check the official source linked above.